Short Interest in Mainz Biomed NV (NASDAQ:QUCY) Decreases By 85.5%
by Doug Wharley · The Cerbat GemMainz Biomed NV (NASDAQ:QUCY – Get Free Report) saw a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 1,522,115 shares, a drop of 85.5% from the May 14th total of 10,530,990 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average daily volume of 15,034,560 shares, the days-to-cover ratio is presently 0.1 days.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.
Get Our Latest Research Report on Mainz Biomed
Mainz Biomed Stock Performance
Mainz Biomed stock traded down $0.02 during midday trading on Thursday, hitting $1.90. 16,284,634 shares of the company’s stock were exchanged, compared to its average volume of 10,394,991. Mainz Biomed has a 12-month low of $0.30 and a 12-month high of $4.93. The stock has a market cap of $27.85 million, a PE ratio of -0.04 and a beta of 2.22. The business has a 50 day moving average price of $1.43.
Mainz Biomed (NASDAQ:QUCY – Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.13 million for the quarter.
About Mainz Biomed
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.